1. Шальнова С.А. Проблемы лечения артериальной гипертонии. Кардиоваскул. терапия и профилактика. 2003; 3: 17–21.
2. Кобалава Ж.Д., Гудков К.М. Гипертонические кризы: существуют ли реальные противоречия в классификации и лечении? Сердце. 2003; 2 (3): 116–27.
3. Колос И.П., Чазова И.Е., Терещенко С.Н. и др. Риск сердечно-сосудистых осложнений у больных частыми гипертоническими кризами. Тер. арх. 2009; 81 (9): 9–12.
4. McRae RPJ, Liebson PR. Hypertensive crisis. Med Clin North Am 1986; 70: 749–67.
5. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356: 411–7.
6. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131: 1949–62.
7. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ/ВНОК. Системные гипертензии. 2010; 3: 5–26.
8. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. A Public Healt 1988; 78: 636–40.
9. Reisch N, Peczkowska M, Januszewicz A et al. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 2006; 24 (12): 2331–9.
10. Cryer PE. Phaeochromocytoma. Clin Endocrinol Metab 1985; 14 (1): 203–20.
11. Mannelli M, Ianni L, Cilotti A et al. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999; 141 (6): 619–24.
12. Mosso L, Carvajal C, Gonzales A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
13. Чазова И.Е., Фомин В.В. Резистентная артериальная гипертензия. Тер. арх. 2008; 6: 80–5.
14. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001; 14 (12): 1263–9.
15. Tisdale JE, Huang MB, Borzak S et al. Risk factors for hypertensive crisis: importance of out-patient blood pressure control. Fam Pract 2004; 21: 420–4.
16. Shea S, Misra D, Ehrlich MH et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority populaton. N Engl J Med 1992; 327: 776–81.
17. Tumlin JA, Dunbar LM, Oparil S et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial: Fenoldopam Study Group. Acad Emerg Med 2000; 7: 653–62.
18. Терещенко С.Н. Гипертонические кризы: диагностика и лечение. Руководство по артериальной гипертонии. М.: Медиа Медика, 2005; с. 676–89.
19. Grossman E, Messerli FH, Grodzicki T et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328–31.
20. Buch J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther 2010; 27 (7): 426–43.
21. Hess W, Schulte-Sasse U, Tarnow J et al. Comparison of phentolamine and urapidil in controlling acute intra-operative hypertension in patients subjected to coronary artery bypass surgery. Eur J Anaesthesiol 1985; 2 (1): 21–7.
22. Stoschitzky K, Stoschitzky G, Wonisch M et al. Differential effects of urapidil and doxazosin on heart rate. Eur J Clin Pharmacol 2007; 63 (3): 259–62.
23. Wacker JR, Wagner BK, Briese V et al. Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol 2006; 127 (2): 160–5.
24. Wacker J, Werner P, Walter-Sack I, Bastert G. Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. Nephrol Dial Transplant 1998; 13 (2): 318–25.
25. Woisetschläger C, Bur A, Vlcek M et al. Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens 2006; 20 (9): 707–9.
26. Adnot S, Andrivet P, Piquet J et al. The effects of urapidil therapy on hemodynamics and gas exchange in exercising patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am Rev Respir Dis 1988; 137 (5): 1068–74.

В.В.Фомин 

ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ